August 18, 2020

The Manager- Listing
**BSE Limited**
Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing
**National Stock Exchange of India Limited**
Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Marketing Authorization) from Drugs Controller General of India (DCGI) for Olaparib Film-Coated tablets 100 mg and 150 mg for Additional indication.

This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (**Marketing Authorization**) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent.

The receipt of this Import and Market permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza®) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For **AstraZeneca Pharma India Limited**

Pratap Rudra
Company Secretary & Legal Counsel